These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
392 related articles for article (PubMed ID: 23835618)
61. The Role of Interleukin-1-Receptor-Antagonist in Bladder Cancer Cell Migration and Invasion. Schneider L; Liu J; Zhang C; Azoitei A; Meessen S; Zheng X; Cremer C; Gorzelanny C; Kempe-Gonzales S; Brunner C; Wezel F; Bolenz C; Gunes C; John A Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070905 [TBL] [Abstract][Full Text] [Related]
62. Loss of GDF10/BMP3b as a prognostic marker collaborates with TGFBR3 to enhance chemotherapy resistance and epithelial-mesenchymal transition in oral squamous cell carcinoma. Cheng CW; Hsiao JR; Fan CC; Lo YK; Tzen CY; Wu LW; Fang WY; Cheng AJ; Chen CH; Chang IS; Jiang SS; Chang JY; Lee AY Mol Carcinog; 2016 May; 55(5):499-513. PubMed ID: 25728212 [TBL] [Abstract][Full Text] [Related]
63. A potential role for 6-sulfo sialyl Lewis X in metastasis of bladder urothelial carcinoma. Taga M; Hoshino H; Low S; Imamura Y; Ito H; Yokoyama O; Kobayashi M Urol Oncol; 2015 Nov; 33(11):496.e1-9. PubMed ID: 26137907 [TBL] [Abstract][Full Text] [Related]
64. Activation of RAS family genes in urothelial carcinoma. Boulalas I; Zaravinos A; Karyotis I; Delakas D; Spandidos DA J Urol; 2009 May; 181(5):2312-9. PubMed ID: 19303097 [TBL] [Abstract][Full Text] [Related]
65. α4 contributes to bladder urothelial carcinoma cell invasion and/or metastasis via regulation of E-cadherin and is a predictor of outcome in bladder urothelial carcinoma patients. Liu J; Cai M; Chen J; Liao Y; Mai S; Li Y; Huang X; Liu Y; Zhang J; Kung H; Zeng Y; Zhou F; Xie D Eur J Cancer; 2014 Mar; 50(4):840-51. PubMed ID: 24388773 [TBL] [Abstract][Full Text] [Related]
66. ppGalNAc T1 as a potential novel marker for human bladder cancer. Ding MX; Wang HF; Wang JS; Zhan H; Zuo YG; Yang DL; Liu JY; Wang W; Ke CX; Yan RP Asian Pac J Cancer Prev; 2012; 13(11):5653-7. PubMed ID: 23317233 [TBL] [Abstract][Full Text] [Related]
67. Knockdown of HMGN5 suppresses the viability and invasion of human urothelial bladder cancer 5637 cells in vitro and in vivo. Gan Y; Tan J; Yang J; Zhou Y; Dai Y; He L; Yao K; Tang Y Med Oncol; 2015 Apr; 32(4):136. PubMed ID: 25796505 [TBL] [Abstract][Full Text] [Related]
68. Expression and function analysis of indoleamine 2 and 3-dioxygenase in bladder urothelial carcinoma. Yang C; Zhou Y; Zhang L; Jin C; Li M; Ye L Int J Clin Exp Pathol; 2015; 8(2):1768-75. PubMed ID: 25973066 [TBL] [Abstract][Full Text] [Related]
69. CEBPD amplification and overexpression in urothelial carcinoma: a driver of tumor metastasis indicating adverse prognosis. Wang YH; Wu WJ; Wang WJ; Huang HY; Li WM; Yeh BW; Wu TF; Shiue YL; Sheu JJ; Wang JM; Li CF Oncotarget; 2015 Oct; 6(31):31069-84. PubMed ID: 26307680 [TBL] [Abstract][Full Text] [Related]
70. Knockdown of long noncoding RNA FGFR3- AS1 induces cell proliferation inhibition, apoptosis and motility reduction in bladder cancer. Liao X; Chen J; Liu Y; He A; Wu J; Cheng J; Zhang X; Lv Z; Wang F; Mei H Cancer Biomark; 2018 Feb; 21(2):277-285. PubMed ID: 29226855 [TBL] [Abstract][Full Text] [Related]
72. Tetracycline-inducible shRNA targeting antisense long non-coding RNA HIF1A-AS2 represses the malignant phenotypes of bladder cancer. Chen M; Zhuang C; Liu Y; Li J; Dai F; Xia M; Zhan Y; Lin J; Chen Z; He A; Xu W; Zhao G; Guo Y; Cai Z; Huang W Cancer Lett; 2016 Jun; 376(1):155-64. PubMed ID: 27018306 [TBL] [Abstract][Full Text] [Related]
73. Differential regulation of bladder cancer growth by various glucocorticoids: corticosterone and prednisone inhibit cell invasion without promoting cell proliferation or reducing cisplatin cytotoxicity. Ishiguro H; Kawahara T; Zheng Y; Kashiwagi E; Li Y; Miyamoto H Cancer Chemother Pharmacol; 2014 Aug; 74(2):249-55. PubMed ID: 24880571 [TBL] [Abstract][Full Text] [Related]
74. Long intergenic non-coding RNA TUG1 is overexpressed in urothelial carcinoma of the bladder. Han Y; Liu Y; Gui Y; Cai Z J Surg Oncol; 2013 Apr; 107(5):555-9. PubMed ID: 22961206 [TBL] [Abstract][Full Text] [Related]
75. The Involvement of Hepatocyte Growth Factor-MET-Matrix Metalloproteinase 1 Signaling in Bladder Cancer Invasiveness and Proliferation. Effect of the MET Inhibitor, Cabozantinib (XL184), on Bladder Cancer Cells. Shintani T; Kusuhara Y; Daizumoto K; Dondoo TO; Yamamoto H; Mori H; Fukawa T; Nakatsuji H; Fukumori T; Takahashi M; Kanayama H Urology; 2017 Mar; 101():169.e7-169.e13. PubMed ID: 28013036 [TBL] [Abstract][Full Text] [Related]
76. Expression of transcription factor Twist1 in bladder urothelial carcinoma and its clinical significance. Tang X; Xing J; Li W; Wu Z; Zhang K; Zheng J J BUON; 2013; 18(1):211-9. PubMed ID: 23613408 [TBL] [Abstract][Full Text] [Related]
77. Down-regulation of HMGB1 expression by shRNA constructs inhibits the bioactivity of urothelial carcinoma cell lines via the NF-κB pathway. Huang Z; Zhong Z; Zhang L; Wang X; Xu R; Zhu L; Wang Z; Hu S; Zhao X Sci Rep; 2015 Aug; 5():12807. PubMed ID: 26239046 [TBL] [Abstract][Full Text] [Related]
78. DDR2 overexpression in urothelial carcinoma indicates an unfavorable prognosis: a large cohort study. Tsai MC; Li WM; Huang CN; Ke HL; Li CC; Yeh HC; Chan TC; Liang PI; Yeh BW; Wu WJ; Lim SW; Li CF Oncotarget; 2016 Nov; 7(48):78918-78931. PubMed ID: 27793038 [TBL] [Abstract][Full Text] [Related]
79. Expression parameters of the polycomb group proteins BMI1, SUZ12, RING1 and CBX7 in urothelial carcinoma of the bladder and their prognostic relevance. Hinz S; Kempkensteffen C; Christoph F; Krause H; Schrader M; Schostak M; Miller K; Weikert S Tumour Biol; 2008; 29(5):323-9. PubMed ID: 18984978 [TBL] [Abstract][Full Text] [Related]
80. High expression of Notch ligand Jagged2 is associated with the metastasis and recurrence in urothelial carcinoma of bladder. Li W; Liu M; Feng Y; Huang YF; Xu YF; Che JP; Wang GC; Zheng JH Int J Clin Exp Pathol; 2013; 6(11):2430-40. PubMed ID: 24228105 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]